Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

Cancers of the genitourinary (GU) tract are common malignancies in both men and women and are a major source of morbidity and mortality. Immune checkpoint inhibitors (ICI) targeting CTLA-4, PD-1 or PD-L1 have provided clinical benefit, particularly in renal cell and urothelial carcinoma, and have be...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brian W. Labadie, Arjun V. Balar, Jason J. Luke
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	immunotherapy immune checkpoint inhibitors genitourinary cancer kidney prostate testicular Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4387b585673943f7b8e9440cd8d6dd21
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4387b585673943f7b8e9440cd8d6dd21
record_format	dspace
spelling	oai:doaj.org-article:4387b585673943f7b8e9440cd8d6dd212021-11-11T15:30:45ZImmune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers10.3390/cancers132154152072-6694https://doaj.org/article/4387b585673943f7b8e9440cd8d6dd212021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5415https://doaj.org/toc/2072-6694Cancers of the genitourinary (GU) tract are common malignancies in both men and women and are a major source of morbidity and mortality. Immune checkpoint inhibitors (ICI) targeting CTLA-4, PD-1 or PD-L1 have provided clinical benefit, particularly in renal cell and urothelial carcinoma, and have been incorporated into standard of care treatment in both localized and metastatic settings. However, a large fraction of patients do not derive benefit. Identification of patient and tumor-derived factors which associate with response have led to insights into mechanisms of response and resistance to ICI. Herein, we review current approvals and clinical development of ICI in GU malignancies and discuss exploratory biomarkers which aid in personalized treatment selection.Brian W. LabadieArjun V. BalarJason J. LukeMDPI AGarticleimmunotherapyimmune checkpoint inhibitorsgenitourinary cancerkidneyprostatetesticularNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5415, p 5415 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunotherapy immune checkpoint inhibitors genitourinary cancer kidney prostate testicular Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immunotherapy immune checkpoint inhibitors genitourinary cancer kidney prostate testicular Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Brian W. Labadie Arjun V. Balar Jason J. Luke Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
description	Cancers of the genitourinary (GU) tract are common malignancies in both men and women and are a major source of morbidity and mortality. Immune checkpoint inhibitors (ICI) targeting CTLA-4, PD-1 or PD-L1 have provided clinical benefit, particularly in renal cell and urothelial carcinoma, and have been incorporated into standard of care treatment in both localized and metastatic settings. However, a large fraction of patients do not derive benefit. Identification of patient and tumor-derived factors which associate with response have led to insights into mechanisms of response and resistance to ICI. Herein, we review current approvals and clinical development of ICI in GU malignancies and discuss exploratory biomarkers which aid in personalized treatment selection.
format	article
author	Brian W. Labadie Arjun V. Balar Jason J. Luke
author_facet	Brian W. Labadie Arjun V. Balar Jason J. Luke
author_sort	Brian W. Labadie
title	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
title_short	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
title_full	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
title_fullStr	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
title_full_unstemmed	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
title_sort	immune checkpoint inhibitors for genitourinary cancers: treatment indications, investigational approaches and biomarkers
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/4387b585673943f7b8e9440cd8d6dd21
work_keys_str_mv	AT brianwlabadie immunecheckpointinhibitorsforgenitourinarycancerstreatmentindicationsinvestigationalapproachesandbiomarkers AT arjunvbalar immunecheckpointinhibitorsforgenitourinarycancerstreatmentindicationsinvestigationalapproachesandbiomarkers AT jasonjluke immunecheckpointinhibitorsforgenitourinarycancerstreatmentindicationsinvestigationalapproachesandbiomarkers
_version_	1718435234961162240

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

Ejemplares similares